Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $13

Benzinga · 2d ago
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $9 to $13.